Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Lynx Therapeutics

Executive Summary

Lynx Therapeutics: Glaxo Wellcome is terminating 1994 licensing agreement between Hayward, Calif.-based Lynx and the Wellcome Foundation that covers the development and marketing of Lynx' antisense drug candidate for the prevention of restenosis following coronary angioplasty or balloon dilation. Lynx reports Jan. 11 that the termination is effective March 17. Glaxo Wellcome says the phosphorothioate oligonucleotide is "no longer a good fit" with its pipeline. Lynx is studying the compound in a Phase I trial in Argentina, accruing 60 patients...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts